Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides

2.1 Icosapent ethyl (Vazkepa, Amarin Corporation) is indicated 'to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL [1.7mmol/l]) and:

2.2 The dosage schedule is available in the summary of product characteristics for icosapent ethyl.

2.3 Icosapent ethyl costs £144.21 per pack of 120 capsules (excluding VAT; company submission). Costs may vary in different settings because of negotiated procurement discounts.